NEW YORK, Feb 4 : The software sector's deepening selloff on Wednesday failed to lure bargain hunters, with the dip-buying reflex that has rescued countless tech routs conspicuously absent. After a ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. MONTREAL—Grass Valley and NETGEAR have announced a strategic partnership to serve the ...

The scale of Common Vulnerabilities and Exposures (CVE) reporting has grown exponentially during 2025, making it another record year in the domain. According to Jerry Gamblin, principal engineer at ...

What’s surprised you the most about the media technology industry in 2025? What has surprised us most in 2025 is the pace at which broadcasters are moving toward software-based, IP-driven production ...

As India prepares to begin commercial chip production by late 2025, much of the discussion has focused on new fabs in Gujarat. Save my User ID and Password Some subscribers prefer to save their log-in ...

Thousands of networks—many of them operated by the US government and Fortune 500 companies—face an “imminent threat” of being breached by a nation-state hacking group following the breach of a major ...

Thousands of networks—many of them operated by the US government and Fortune 500 companies—face an “imminent threat” of being breached by a nation-state hacking group following the breach of a major ...

Internet Protocol (IP) is a numerical identifier for every gadget or network for users accessing the internet. The IP address of a user contains information like location, network identification, ...

The European Broadcasting Union (EBU), Linux and NABA have announced a collaboration on an open source MXL software development kit. Recognising a need for native live media exchange on local or ...

Lumens Digital Optics has announced that its OIP-N40E IP transcoder is now Dante ready. This enables it to route and convert Dante video and transmit Dante audio bi-directionally over a standard ...

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced further progress on Thursday in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. To date, 13 patients have received at ...